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Background: Polycomb group (PcG) proteins are histone modifiers known to transcriptionally silence key tumour suppressor
genes in multiple human cancers. The chromobox proteins (CBX2, 4, 6, 7, and 8) are critical components of PcG-mediated
repression. Four of them have been associated with tumour biology, but the role of CBX2 in cancer remains largely
uncharacterised.
Methods: Addressing this issue, we conducted a comprehensive and unbiased genotranscriptomic meta-analysis of CBX2 in
human cancers using the COSMIC and Oncomine databases.
Results: We discovered changes in gene expression that are suggestive of a widespread oncogenic role for CBX2. Our genetic
analysis of 8013 tumours spanning 29 tissue types revealed no inactivating chromosomal aberrations and only 40 point mutations
at the CBX2 locus. In contrast, the overall rate of CBX2 amplification averaged 10% in all combined neoplasms but exceeded 30%
in ovarian, breast, and lung tumours. In addition, transcriptomic analyses revealed a strong tendency for increased CBX2 mRNA
levels in many cancers compared with normal tissues, independently of CDKN2A/B silencing. Furthermore, CBX2 upregulation
and amplification significantly correlated with metastatic progression and lower overall survival in many cancer types, particularly
those of the breast.
Conclusions: Overall, we report that the molecular profile of CBX2 is suggestive of an oncogenic role. As CBX2 has never been
studied in human neoplasms, our results provide the rationale to further investigate the function of CBX2 in the context of cancer
cells.
Recent advances in DNA sequencing technologies have allowed
unprecedented insights into the genomic landscape of human
tumours (Meyerson et al, 2010). A unifying theme is emerging:
cancers display extensive inter- and intra-tumoral genetic hetero-
geneity, with very few neoplasms resulting from a single recurrent
genomic aberration (Gerlinger et al, 2012; Swanton, 2012).
In parallel with those observations, many lines of evidence
suggest that cancers may be driven by alterations that are
epigenetic in nature, that is, they do not alter the primary DNA
sequence (McDonald et al, 2011; Timp and Feinberg, 2013).
As epigenetic modifications are reversible and can be pharma-
cologically targeted (Crea et al, 2011; Kim et al, 2013),
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identifying the epigenetic drivers of cancer progression is thus a
matter of utmost importance.
In the past decade, a number of chromatin regulators known to
have key molecular functions in embryonic development have been
identified as novel cancer-promoting genes (Varambally et al,
2002; You et al, 2009). These epigenetic factors are thought to
retain cancer cells in an undifferentiated state, thus enhancing their
metastatic potential and resistance to treatment (Ben-Porath et al,
2008; Ohm et al, 2007). The Polycomb group (PcG) family
represents the typical example of such genes, as they can silence
lineage-specific genes both in embryonic stem cells and multiple
cancer types (Bracken and Helin, 2009). Polycomb group genes
encode transcriptional repressors that assemble in a complex
combinatorial manner to form two main Polycomb repressive
complexes (PRC1 and PRC2) (Satijn et al, 1997; Kuzmichev et al,
2002). In the classical model of PcG-mediated silencing, PRC2
trimethylates histone H3 at lysine 27 (H3K27me3) through the
action of its catalytically active subunit EZH2 (Cao et al, 2002).
H3K27me3 can be directly recognised by one of five chromodo-
main-containing proteins (CBX2, 4, 6, 7 and 8), which subse-
quently recruit PRC1 to chromatin by simultaneously interacting
with the E3 ubiquitin ligase Ring1B through a C-terminal domain
(Kaustov et al, 2011). This interaction brings Ring1B to H3K27me3
sites, where Ring1B ubiquitylates lysine 119 on histone H2A
(H2AK119ub), further repressing transcription at target loci (van
der Stoop et al, 2008). Interestingly, PRCs can also act
independently of each other as recent studies have shown that
PRC1 can silence genomic regions that are not marked by
H3K27me3 (Tavares et al, 2012). Moreover, some CBX-containing
PRC1 complexes are devoid of ubiquitin ligase activity despite
retaining gene-silencing properties (Gao et al, 2012). Although PcG
proteins may act through different pathways in different cancer
types, PcG gain of function generally associates with an
undifferentiated cellular state and aggressive clinical behaviour
(Boyer et al, 2006).
Whereas EZH2 and BMI-1 have been the two most heavily
investigated PcG genes in the context of human neoplasms
(Bachmann et al, 2006; Cao et al, 2011), emerging evidence
supports a critical role for the CBX proteins in cancer initiation
and progression. All CBX family members share a conserved
N-terminal chromodomain but display non-homologous
sequences in their C-terminus, accounting for their non-redundant
functions (Vincenz and Kerppola, 2008). Distinct CBX proteins
interact with a wide range of macromolecules including DNA,
non-coding RNAs, and numerous other proteins (Bernstein et al,
2006; Vandamme et al, 2011). Furthermore, individual CBX family
members can be differentially expressed, undergo alternative
splicing, harbour distinct post-translational modifications, and lie
under the control of different microRNAs (O’Loghlen et al, 2012).
All of these regulatory steps affect the function of individual CBX
protein and allow for tremendous complexity in PRC1 activity and
sequence specificity.
Individual CBX proteins are defined by distinct C-terminal
sequences that underlie their specific properties. The structural
differences between the CBX family members are also reflected in
the diversity of molecular functions they can accomplish in the
context of cancer cells. For example, CBX4 possesses SUMO
activity and is thought to have important roles in cellular
proliferation and DNA damage repair in some human tumours
(Yang et al, 2011; Wang et al, 2013). Conversely, SNPs in CBX6
have been reported in genome-wide association studies (GWASs)
of bladder cancer although their functional implications have not
been fully elucidated (Rothman et al, 2010). CBX7 has been the
most extensively investigated CBX family member and exhibits
cancer type-specific activity in human tumours. Most studies
report a widespread oncosuppressive function (Forzati et al,
2012a), notably in brain (Gargiulo et al, 2013), colon (Pallante et al,
2010), and lung cancers (Forzati et al, 2012b). However, other
investigations have revealed an oncogenic role for CBX7
(Mohammad et al, 2009; Zhang et al, 2010) occurring mainly
through silencing of CDKN2A and CDKN2B loci, which encode
the cyclin-dependent kinase inhibitors p14ARF, p15INK4B, and
p16INK4A (Bernard et al, 2005). Finally, CBX8 was found to be
essential for MLL/AF9 leukemogenesis (Tan et al, 2011) in
addition to its ability to silence the CDKN2A locus (Dietrich
et al, 2007). Despite solid evidence implicating these four CBX
family members in neoplastic transformation, no study has directly
addressed the role of CBX2 in human cancers.
Emerging evidence supports a role for CBX2 in cellular
proliferation. Loss of M33, the murine CBX2 ortholog, impairs
progression through the S phase of cell cycle in an E2F-dependent
mechanism, which is consistent with the decreased cellularity of
hematopoietic organs in M33-KO mice (Core´ et al, 2004). In
addition, CBX2 directly binds the tumour-suppressive CDKN2A
and CDKN2B loci in young and proliferative fibroblasts but
progressively becomes absent from this chromosomal region as the
cells undergo senescence and cell cycle arrest (Agherbi et al, 2009).
Furthermore, experiments conducted in mice have demonstrated
that unphosphorylated M33 is present in the cytoplasm of mature
hepatocytes, but becomes phosphorylated and translocates to the
nucleus in proliferative hepatocytes during the liver regeneration
(Noguchi et al, 2002). Interestingly, studies have shown that CBX2
phosphorylation also increases its affinity to H3K27me3 in
addition to inducing its nuclear translocation, which is consistent
with cell cycle-dependent regulation of CBX2 activity (Hatano
et al, 2010). Finally, Grau et al have demonstrated that CBX2 is the
only human CBX family member able to induce chromatin
compaction (Grau et al, 2011). Elegant studies based on electron
microscopy have revealed that this feature of CBX2 has mediated a
highly positively charged region located in its C-terminus not
found in any other PcG member, thus suggesting a unique and
crucial function for CBX2 in PcG-mediated repression.
On the basis of the critical role played by CBX2 in cellular
proliferation and the emerging evidence implicating Polycomb-
mediated silencing in tumour biology, we postulated that CBX2
may represent an important component in cancer initiation and
progression. Given the lack of literature addressing the implica-
tions of CBX2 in a neoplastic context, we conducted a meta-
analysis of CBX2 in human cancers at the genomic and
transcriptomic level using publicly available databases. We report
that CBX2 downregulation and inactivating genetic mutations
represent extremely rare events in human tumours. Furthermore,
we also provide the first evidence that CBX2 genomic amplification
and mRNA upregulation predict metastatic progression and poor
overall survival (OS) in multiple cancer types, notably those arising
from the breast.
MATERIALS AND METHODS
COSMIC database analysis. The COSMIC database (http://
cancer.sanger.ac.uk/cancergenome/projects/cosmic/) (Forbes et al,
2008) was used to extract all data relevant to our analysis of genetic
alterations at the CBX2 locus. All data were collected after 20
October 2013, and a final revision of all acquired data was
performed between 1 July and 21 July 2013. All data originating
from the COSMIC database are specifically mentioned either in the
main text, the figure legend, or both. All the raw data extracted
from the COSMIC database can be found in Supplementary
Information.
Oncomine database analysis. All transcriptomic data used in this
manuscript were extracted from the Oncomine platform (www.
oncomine.com) (Rhodes et al, 2004) after 20 October 2013, and a
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final revision of all acquired data was performed between 1 July
and 21 July 2013. Data were acquired in an unbiased manner by
compiling all the Oncomine studies that showed significantly
altered CBX2 expression at the threshold set for each individual
analysis. Significant studies in which at least one analysed group
was comprised of three patients or less were excluded. All data
originating from the Oncomine database are specifically mentioned
either in the main text, the figure legend, or both. All the raw data
extracted from the Oncomine database can be found in
Supplementary Information.
Human Protein Atlas database analysis. The image of CBX2
protein sequence and domains used in Supplementary Figure S1
was obtained from the Protein Atlas database (http://www.protei-
natlas.org/) (Uhlen et al, 2010).
Assessment of clinical correlations for genes within the minimal
common region (MCR) of CBX2 amplification. TCGA breast
cancer copy number data were downloaded from Cancer
Genomics Browser (https://genome-cancer.ucsc.edu/) and all
tumours containing CBX2 gains were determined. We filtered
the segments with gain (logR40.3) and at least 100 kb in size and
mapped the MCR, defined by the sample with the smallest region
containing CBX2. We then determined the Spearman copy
number–expression correlation for genes mapping to the region
assessed. Those with significant correlation (Po0.05 Spearman)
were further analysed for survival associations using the Curtis
Breast data set on Oncomine and all breast cancer samples from
the KMplotter resource (http://kmplot.com/analysis/) (Mihaly
et al, 2013).
Statistical analysis. Unless otherwise mentioned, all analyses were
done using Pp0.05 as the significance threshold. GraphPad Prism
software (version 6, GraphPad Software Inc., La Jolla, CA, USA)
was used for all statistical analyses except for the multivariate
analysis of variance (MANOVA) and the Cox proportional hazards
(COXPH) regression, which were done using R statistical software
(GNU, freely available at http://www.r-project.org/).
RESULTS
Genomic analysis of the CBX2 locus. As the first step of our
systematic meta-analysis to study CBX2 expression in human
cancers, we analysed genomic alterations at the CBX2 locus using
the COSMIC database, a resource designed to store and display
somatic mutation information and related details (Forbes et al,
2008). Strikingly, there was an extremely low frequency of
alterations disrupting CBX2 function. In 8013 tumour samples
spanning 29 tissue types, we did not find a single translocation,
homozygous loss, insertion/deletion, or any other inactivating
large-scale chromosomal abnormalities (Figure 1A). In total, only
40 point mutations were recorded at the CBX2 gene in these
tumours (overall frequency¼ 0.5%). The CBX2 mutation fre-
quency is thus considered very low, as high-frequency mutations
are typically described as being over 20% and intermediate
frequency as being between 2 and 20% (Lawrence et al, 2014).
Further analysis revealed that of those 40 mutations, 2 were
nonsense and 22 were missense, whereas 17 were silent mutations,
which did not have any effect on CBX2 protein sequence
(Figure 1B). These point mutations were distributed evenly across
all tissues, with no tumour type having a marked increase in CBX2
mutation frequency (Supplementary Figure S1). The mutations
were concentrated in regions where CBX2 is predicted to be highly
disordered and hydrophilic, and within these regions their
distribution was relatively homogenous (Supplementary Figure
S2). In addition, no single residue within the CBX2 protein was
mutated more than twice. Interestingly, there was a complete
absence of point mutations in the CBX2 chromodomain, the
region responsible for H3K27me3 binding (Supplementary Figure
S2). Overall, the lack of large-scale genomic aberration and the
non-synonymous mutation frequency of 0.3% make it unlikely that
alterations at the CBX2 locus impact cancer cell phenotype.
The low frequency of genomic CBX2 disruption led us to
investigate whether CBX2 copy number increases are favoured
during oncogenesis. To address this question, we first analysed the
amplification profile of the CBX2 locus in human neoplasms using
the COSMIC database. In contrast with the rare nature of CBX2-
inactivating mutations, we uncovered that CBX2 gene amplifica-
tions occur frequently in a number of tumour types. Overall, 714
out of 8013 samples from the COSMIC database had undergone
copy number gain (CNG) at the CBX2 locus (overall frequency:
8.9%; see Figure 2 and Supplementary Table S1). Interestingly, the
distribution of these amplifications was not homogenous across all
tumour types. We observed five neoplasms in which the CBX2
CNG frequency ranged between 3 and 15%: those originating from
the central nervous system, colon, endometrium, pancreas, and
kidneys (Figure 2 and Supplementary Table S1). Furthermore,
three cancer types harboured a frequency of CBX2 amplification
430%: tumours of the ovaries (34.0%), breast (34.5%), and lungs
(35.5%), suggesting that CBX2 copy number increases may provide
a selective advantage to cancer cells.
Transcriptomic analysis of CBX2 expression in human cancers.
As our genomic analysis revealed recurrent CNGs and very rare
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Figure 1. Extremely rare occurrence of genetic mutations disrupting CBX2 function in human cancers (COSMIC database) (A) Percentage of
specific inactivating genetic alterations at the CBX2 locus. (B) Distribution and frequency of CBX2 point mutations.
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inactivating mutations at the CBX2 locus, we next investigated
whether this trend would also be reflected at the mRNA level.
Using the Oncomine database (Supplementary Table S2) (Rhodes
et al, 2004), we identified a total of 25 studies that showed
significant upregulation (FC42, P value o0.001, top 10% over/
underexpressed) in cancer compared with normal tissue (Figure 3
and Supplementary Table S3). Strikingly, not a single study
reported downregulation of CBX2 using the same inclusion criteria
(Figure 3), once again implying an important functional role in
cancer cells. The total number of patients in the 25 studies showing
CBX2 upregulation in cancer tissues is 3848 compared with 0 for
CBX2 downregulation (Figure 3 and Supplementary Table S3). In
the studies harbouring CBX2 overexpression, fold changes varied
between 2.1 and 15, and the P values between 4.0E-3 and 3.6E-73
(Figure 3). The most represented cancer types in the CBX2-
overexpressed studies were those originating from the colon
(29.6%), breast (18.5%), stomach (14.8%), and lungs (11.1%).
These results demonstrate a clear bias towards CBX2 upregulation
and complement the genomic analysis that hinted towards a
selective pressure to maintain CBX2 function.
Polycomb group complexes are known to repress the tumour-
suppressive loci CDKN2A (encoding p14ARF and p16INK4A) and
CDKN2B (encoding p15INK4B) in many human cancers (Aguilo
et al, 2011). We thus sought to determine whether CBX2
overexpression correlated with silencing of the CDKN2A/B genes.
Interestingly, we found that neither p14ARF nor p16INK4A were
downregulated in any of the 25 studies with CBX2 overexpression
(Supplementary Figure S3 and Supplementary Table S4). However,
p15INK4B was found to be downregulated in 10 of those 25 studies
(40%) using the same cut-off as for CBX2 (FC42, P value o0.01,
top 10% underexpressed). Further analysis revealed that 8 of the 10
studies with concomitant CBX2 upregulation and p15INK4B
downregulation occurred specifically in the colorectal cancer
(Supplementary Figure S3 and Supplementary Table S4). However,
when using Spearman correlations to investigate the direct
relationship between CBX2 and CDKN2A/B, not a single study
showed a statistically significant correlation (Table 1, Spearman
correlation of R240.1, even in colorectal cancer). Taken together,
analysis of CBX2 mRNA levels revealed lack of CBX2 down-
regulation contrasted by frequent CBX2 overexpression, an event
that occurred independently of CDKN2A/B silencing.
Clinical correlations of differential CBX2 expression. Given the
widespread CBX2 upregulation in cancerous compared with
normal tissues, we investigated whether CBX2 expression was also
correlated with clinical indicators of tumour progression.
Metastasis was the first parameter we assessed. Using the
Oncomine database (Rhodes et al, 2004), we found nine studies
exhibiting significantly (FCX1.5, Pp0.05) increased CBX2 mRNA
levels in metastatic compared with primary tumours (Table 2).
Prostate cancer (PCa) was the most represented tumour type,
accounting for three of the five most significant studies. Sarcoma
and breast cancer followed with two studies each displaying CBX2
upregulation in metastatic disease. In contrast with the strong
CBX2 upregulation observed in disseminated tumours, not a single
study with CBX2 underexpression could be detected using the
same parameters (Table 2), consistent with a selection against
CBX2 loss of function in metastatic cells.
Next, we investigated whether differential CBX2 expression and
genomic copy number were associated with poor clinical outcome
in human malignancies. We queried the Oncomine database for
studies in which CBX2 mRNA levels were significantly altered
between alive and deceased patients at 1, 3, and 5 years after
diagnosis using an FC41.2 and Po0.05 as inclusion criteria
(Supplementary Table S5). After 1 year, the number of studies with
CBX2 overexpression (eight) was almost two-fold higher than
those with CBX2 underexpression (five) (Figure 4A and
Supplementary Table S5). Furthermore, there was a striking
difference between the number of studies in which CBX2 mRNA
was upregulated compared with those which displayed CBX2
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downregulation in patients who were deceased compared with
those who were alive at 3 and 5 years post diagnosis (17/1 and
16/2, respectively, see Figure 4A and Supplementary Table S5).
To ensure that the number of studies showing CBX2 upregulation
was higher than those with CBX2 downregulation across all three
time points, we performed a chi-square test and found a
statistically significant difference between the studies with high
and low CBX2 (Po0.00001, chi-square). Interestingly, some cancer
types in particular showed a recurrent inverse correlation between
high CBX2 mRNA levels and lower OS. Notably, tumours of the
breast (five and five), central nervous system (two and two), and
lungs (one and three) were among the most represented cancer
types for this analysis at 3 and 5 years, respectively (Figure 4A). We
also found three studies of head and neck tumours in which
significantly decreased, not increased, levels of CBX2 led to lower
OS. In addition, CBX2 CNG could also be associated with clinical
outcome. Analysis of the Oncomine database revealed an increase
in CBX2 copy number in metastatic compared with primary
pancreatic cancer (Supplementary Figure S4, Po0.001). Moreover,
CBX2 CNG was also inversely correlated with OS in oligoastro-
cytoma and ovarian cancer at 3 years (Supplementary Figure S4,
P¼ 0.02 for both), and in oligoastrocytoma at 5 years
(Supplementary Figure S4, P¼ 0.02). Thus, our results demon-
strate that both CBX2 gene amplification and mRNA upregulation
may harbour prognostic significance.
To further assess the relationship between CBX2 and individual
clinical variables, we conducted a MANOVA in one cohort for
each of the breast, lung, and colorectal cancers from the Oncomine
platform. All significant covariates (Po0.05) in the MANOVA
were further assessed using univariate analyses. We found that
CBX2 was significantly associated with sex in the colon cancer,
with higher expression observed in females (Supplementary Table S6,
TCGA colorectal, Po0.01, Mann–Whitney U-test). In the
analysed lung cancer data set, subtype was the only clinical
covariate associating with CBX2, with higher CBX2 expression in
squamous cell carcinoma compared with lung adenocarcinoma
(Supplementary Table S7, Bild Lung, Po0.05, Mann–Whitney
U-test). Finally, MANOVA conducted on the Curtis Breast data set
revealed a highly significant association between CBX2 and age,
subtype, and grade that was confirmed via Kruskal–Wallis test
(Supplementary Table S8, all Pso10 15, Kruskal–Wallis test).
More specifically, higher CBX2 expression correlated with younger
age, basal-like subtype, and higher grade, all of which are linked to
poor patient prognosis. We therefore conducted a COXPH
regression on the Curtis Breast data set to further explore the
relationship between CBX2 and clinical outcome. Interestingly, we
found that behind age, CBX2 was the second covariate most
significantly associated with patient survival (Table 3, COXPH,
Po0.001), suggesting a role for CBX2 in promoting aggressive
disease progression.
Finally, we investigated whether CBX2 is a potential driver of
the recurrent 17q25.3 copy gains we observed. We used multiple
criteria to investigate genes mapping to the MCR of amplification
containing CBX2, including copy number expression association,
expression in tumours compared with normals, and survival
association, as these features could highlight the gene that is most
likely to be driving the 17q25.3 amplicon. As CBX2 was recurrently
amplified and differentially expressed in breast cancer, we
investigate the clinical implications of the CBX2 amplicon in
breast cancer. We first used breast cancer TCGA copy number data
from the Cancer Genomics Browser (Zack et al, 2013; https://
genome-cancer.ucsc.edu/) to identify all gained genomic segments
containing CBX2. We then filtered the segments with gain (defined
Table 2. List of studies with differential CBX2 expression between metastatic and primary tumours
Alteration Rank Study name Cancer type Primary, n Metastatic, n Total, n Fold change P-value
Upregulation 1 Chandran prostate Prostate cancer 10 21 31 7.8 1.7E-12
2 Bittner breast Breast cancer 327 9 336 1.9 3.2E–05
3 Varambally prostate Prostate cancer 7 6 13 9.2 1.3E–04
4 Segal sarcoma 2 Sarcoma 46 4 50 13 4.4E–04
5 Grasso prostate Prostate cancer 13 17 30 1.9 4.0E–03
6 Riker melanoma Melanoma 16 40 56 1.6 6.0E–03
7 Radvanyi breast Breast cancer 41 4 45 3.1 9.0E–03
8 Bittner sarcoma Sarcoma 42 10 52 1.7 1.1E–02
9 Liao liver Liver cancer 4 6 10 4.9 2.3E–02
Downregulation — None found — — — — —
Oncomine database; inclusion criteria: FCX1.5, Pp0.05, top 10% under/overexpressed, Student’s t-test.
Table 1. Spearman correlation between CBX2 and CDKN2A/B in the dat
sets displaying CBX2 upregulation in malignant compared with normal
tissues
Data set Patients, n R2 CDKN2A R2 CDKN2B
Brune lymphoma 42 0.00 0.05
Cho gastric 71 0.02 0.07
Crabtree uterus 50 0.05 0.01
Curtis breast 1992 0.01 0.00
Derrico gastric 38 0.02 0.00
Hong colorectal 70 0.04 0.00
Hou lung 91 0.00 0.01
Korkola seminoma 101 0.02 0.01
Lee bladder 188 0.01 0.04
Richardson breast 2 40 0.12 0.02
Skrzypczak colorectal 81 0.01 0.03
Skrzypczak colorectal 2 20 0.03 0.01
Sun brain 157 0.01 0.00
TCGA breast 532 0.11 0.05
TCGA colorectal 215 0.00 0.00
Abbreviation: CDKN¼ cyclin-dependent kinase inhibitor.
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by having a log ratio40.3) and at least 100 kb in size and mapped
the MCR, which is defined by the sample with the smallest region
containing CBX2. We found that the MCR contained three genes:
ENPP7, CBX2, and CBX8, present at 17q25.3 (Figure 5A and B).
We next assessed the correlation between copy number and the
expression of genes mapping to the region using Spearman
correlation. ENPP7 had a negative correlation, indicating that its
amplification did not result in increased expression. In contrast, a
weak but significant positive correlation was observed for both
CBX2 and CBX8 (Supplementary Table S9, Po0.0001, Spearman).
To determine whether either of the two genes was associated with
patient survival, we performed a Mantel–Cox log-rank test for both
CBX2 and CBX8, comparing survival of patients with expression
ranking in the top and bottom quartiles of expression. We report
that elevated CBX2 levels, but not CBX8, significantly predicts
lower OS in breast cancer (Figure 5C and D, CBX2 Po0.0001;
CBX8 P¼ 0.49, Mantel–Cox log-rank test). were reproducible, we
also performed log-rank test on CBX2 and CBX8 using the
KMplotter (http://kmplot.com/analysis/) (Mihaly et al, 2013).
Once again, we found that CBX2 was the only gene within the
MCR that was able to significantly predict lower OS (Figure 5E and
F, Po0.05, log-rank test). Overall, we demonstrate that CBX2 is
frequently gained in breast cancer, which leads to its increased
expression and associates with poor patient prognosis, suggesting
that it is a candidate driver of the 17q25.3 amplicon.
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Table 3. Cox proportional hazards regression for CBX2 in Curtis Breast
data set
Curtis breast Coef exp(coef)
s.e.
(coef) z P-value
CBX2 0.108 1.11 0.03369 3.205 0.0013
Age 0.0316 1.03 0.00312 10.123 0
Grade 2 0.1439 1.15 0.15029 0.957 0.34
Grade 3 0.3413 1.41 0.15505 2.201 0.028
Basal subtype 0.2722 1.31 0.12925 2.106 0.035
Luminal B subtype 0.2495 1.28 0.09536 2.617 0.0089
Her2 subtype 0.3634 1.44 0.12174 2.985 0.0028
Normal subtype 0.2839 1.33 0.13662 2.078 0.038
Abbreviations: CBX2¼ chromobox protein 2; Coef¼ coefficient; exp¼ exponent.
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In summary, genomic analysis has revealed that genetic
alterations resulting in loss of function represent extremely
infrequent events at the CBX2 locus. In contrast, recurrent
amplifications were observed in multiple cancer types. In addition,
transcriptomic analysis revealed a propensity for CBX2 upregula-
tion in the following four independent scenarios: (1) cancer vs
normal tissues; (2) metastatic vs primary tumours; (3) dead vs alive
at 3 years; and (4) dead vs alive at 5 years (Supplementary Table
S10). Surprisingly, with the exception of CDKN2B in the colorectal
cancer, CBX2 overexpression was not correlated with silencing of
the tumour-suppressive CDKN2A or CDKN2B loci.
DISCUSSION
Our results demonstrate a clinically relevant increase in CBX2 copy
number and expression in human cancer. Given the very low
frequency of CBX homozygous loss, point mutation, and under-
expression, we believe CBX2 is likely to have an important
functional role in tumour cells. In parallel, transcriptomic analysis
of CBX2 expression revealed a strong bias towards CBX2
upregulation, although this alteration was observed at different
stages among the various tumour types, indicating some context
specificity in CBX2 activity and binding partners. Overall, breast
cancer displayed the most significant associations with CBX2
alterations, exhibiting an overall frequency of CBX2 amplification
exceeding 30%. We demonstrated that CBX2 copy number
increases correlated with increased CBX2 expression, which is
significantly associated with lower OS. Of all the genes present in
the MCR containing CBX2, only CBX2 has prognostic relevance,
suggesting that CBX2 displays a driving role in the progression of
breast cancer. As CBX2 and CBX8 share a conserved chromodo-
main but largely differ in their C-terminus (Vincenz and Kerppola,
2008), we believe further investigation is required to elucidate the
structural differences that may underlie the potential cancer-
promoting role of CBX2.
Given that many breast cancers also harbour EZH2 gain of
function (Granit et al, 2013; Kleer et al, 2003), an interesting
possibility is that CBX2 upregulation represents a key adaptation
necessary to perpetuate EZH2’s oncogenic activity. This therefore
implies an important role for the ability of CBX2 to interact with
H3K27me3 and is consistent with our observation that missense
mutations are excluded from the chromodomain of CBX2. Given
that chromodomains act as protein–RNA binding modules
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(Akhtar et al, 2000), we also suspect that CBX2 may be interacting
with specific long non-coding RNAs (lncRNAs), which could
fine tune its target specificity in a context-dependent manner.
Interestingly, EZH2 and H3K27me3 also regulate the expression of
several tissue-specific lncRNAs (Wu et al, 2010; Guil et al, 2012).
As many loci encoding lncRNA are rich in AT repeats and CBX2
contains an AT hook domain that can interact with those regions
(Senthilkumar and Mishra, 2009), it is conceivable that EZH2 and
CBX2 directly regulate the lncRNAs that themselves determine
PcG target specificity.
Prostate cancer is another neoplasm in which EZH2 over-
expression represents a key hallmark (Varambally et al, 2002; van
Leenders et al, 2007), and interestingly it was the cancer type in
which CBX2 upregulation most significantly correlated with
metastatic progression. The frequent upregulation of many PcG
family members (van Leenders et al, 2007), coupled with the
prognostic significance of a Polycomb repressive signature in PCa
(Yu et al, 2007), support the idea that PcG complexes undergo gain
of function in metastatic disease. As opposed to breast cancer, we
could not find any significant differential CBX2 expression in
neoplastic tissues compared with normal ones, indicating that
CBX2 upregulation likely represents a late event in PCa
progression. Whereas the presence of metastases represents the
most valuable indicator of PCa prognosis, we did not find any
correlations between CBX2 expression and OS. We attribute this
result to a technical limitation of the Oncomine database, which
can only calculate survival at 1, 3, and 5 years. As PCa is generally a
slow-growing disease and metastases can appear years after initial
diagnosis (Simmons et al, 2011), it is likely that analysing
differences in OS strictly below 5 years post diagnosis may be
too early to achieve statistical significance.
Our results conclusively demonstrate a recurrent CBX2
upregulation frequently correlating with metastasis and lower OS
in numerous cancer types. This analysis paves the way for
functional studies aimed at identifying the molecular mechanisms
through which CBX2 may promote tumour initiation and
progression. However, one limitation of our meta-analysis is that
it does not allow for an in-depth characterisation of subtype-
specific CBX2 expression. For example, it is thus possible that
CBX2 expression is markedly high in one molecularly or
histologically characterised subtype while being low in another
from a given neoplasm, something that could not be determined
from our analysis. Nonetheless, by using the COSMIC and
Oncomine databases we were able to analyse over 40 000 patient
samples in a fully unbiased manner, which allowed us to observe a
genotranscriptomic profile for CBX2 that was consistent with that
of an oncogene.
Finally, the very low frequency of CBX2 mutation and under-
expression suggest that the therapeutic inhibition of CBX2 might
represent a valuable clinical strategy for the treatment of many
human cancers. We report aberrant regulation of CBX2 in the
breast, lung, colorectal, prostate, brain, and haematopoietic tumours,
all of which rank among the 10 deadliest neoplastic diseases
worldwide and are in dire need of novel therapeutics. Furthermore,
epigenetic alterations are reversible and recent studies have high-
lighted the possibility of targeting histone readers with small-
molecule inhibitors (Dawson et al, 2012; Tabet et al, 2013). Taken
together, our work has identified a putative oncogenic role for CBX2
in numerous tumour types and has provided the rationale for the
design of novel CBX2-targeting therapies.
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